Sbtx.L
SBTX.L operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
Business. SBTX.L operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
SBTX.L operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research.
The company's capital structure is characterized by a high price-to-book ratio of 268.27, indicating a significant premium over its book value. Despite holding substantial cash and equivalents of 4,779,430 GBP, the company has a negative operating income of -1,123,130 GBP and a net income of -696,250 GBP, suggesting operational challenges. The liquidity position is strong, as evidenced by a current ratio of 4.84, which is well above the industry median.
Profitability metrics are concerning, with a return on equity of -7.39% and a return on assets of -5.74%, both significantly below the industry median. The company's gross profit of 2,859,280 GBP is a positive aspect, but it is not sufficient to offset the operating and net losses. The debt-to-equity ratio of 0.11 indicates a conservative capital structure, with minimal leverage.
The company's revenue is concentrated in a single segment, as no segmental breakdown is provided, and there is no geographic diversification data available. This lack of diversification could pose a risk if the primary market experiences downturns.
The growth trajectory is uncertain, with no specific revenue growth projections provided. The company's operating cash flow is negative at -1,235,070 GBP, and free cash flow is also negative at -455,250 GBP, indicating a need for external financing to sustain operations. The capital expenditure of -158,830 GBP suggests some investment in growth, but it is minimal.
Risk factors include the company's negative net income and operating income, which could affect its ability to meet financial obligations. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The dilution potential is low, and no adjustments have been applied to the valuation metrics.
Recent events include analyst estimates with a mean price target of 29.00 GBP, indicating a strong positive outlook from analysts despite the company's current financial performance. The mean recommendation of 2.00 suggests a buy rating, with one buy count and no strong buy or hold counts.
- The company has a high price-to-book ratio, indicating a premium valuation.
- Operational performance is weak, with negative operating and net income.
- Liquidity is strong, with a high current ratio.
- Analysts have a positive outlook, with a mean price target significantly higher than the current market price.
- "margin_outlook_rationale": "The company's gross margin is positive, but the operating and net margins are negative, indicating a need for cost control and revenue growth.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- SBTX.L Market data — financials · 2026-05-29
- SkinBioTherapeutics PLC Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Stuart John AshmanChief Executive Officer, Executive Director